Preprint / Version 1

The Use of immunotherapy to treat Classical Hodgins Lymphoma

##article.authors##

  • Karan Naidu Polegence
  • Ashley Pearson

DOI:

https://doi.org/10.58445/rars.1571

Keywords:

Cancer Immunotherapy, biology

Abstract

This research paper goes into what is classical hodgins lymphoma and the aspect of how it works and then digs into the immunotherapies related with this disease and how they work as well. It then dwells into the future aspects and the ongoing clincal trials to help make effienct treatments for CHL.

References

Chenson, B. D., & Barttlet, N. L. (2020, October 1). Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Pubmed. Retrieved June 5, 2024, from https://pubmed.ncbi.nlm.nih.gov/33010817/

Randall, M. P., & Spinner, M. A. (2023, September 11). Optimizing Treatment for Relapsed/Refractory

Classic Hodgkin Lymphoma in the Era of Immunotherapy. Pubmed. Retrieved June 15, 2024, from

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526852/

Cooper, M. R., & Almalki, B. (2017, June 25). Nivolumab for the Treatment of Classical Hodgkin

Lymphoma. Pubmed. Retrieved June 7, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/

PMC5998472/

Stages of Hodgkin lymphoma. (n.d.). Cancer Research UK. https://www.cancer.org/cancer/types/

hodgkin-lymphoma/treating/monoclonal-antibodies.html

Ansell, S. M. (2017, April 7). Nivolumab in the Treatment of Hodgkin Lymphoma. Aacr Journals.

Retrieved June 5, 2024, from https://aacrjournals.org/clincancerres/article/23/7/1623/80686/

Nivolumab-in-the-Treatment-of-Hodgkin

Haemetol, E. J. (2016, May 30). Pembrolizumab in classical Hodgkin's lymphoma. Pubmed. Retrieved

June 5, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987237/

Armand, P., & Ansell, S. M. (2018, March 27). ivolumab for Relapsed/Refractory Classic Hodgkin

Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of

the Multicohort Single-Arm Phase II CheckMate 205 Trial. Asco Pubs. Retrieved june 4, 2024,

from https://ascopubs.org/doi/10.1200/JCO.2017.76.0793

Downloads

Posted

2024-09-05

Categories

License

Copyright (c) 2024 Karan Naidu, Ashley Pearson

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license